Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

The Role of MDM2 Amplification and Overexpression in Tumorigenesis.

Oliner JD, Saiki AY, Caenepeel S.

Cold Spring Harb Perspect Med. 2016 Jun 1;6(6). pii: a026336. doi: 10.1101/cshperspect.a026336. Review.

2.

Identifying the determinants of response to MDM2 inhibition.

Saiki AY, Caenepeel S, Cosgrove E, Su C, Boedigheimer M, Oliner JD.

Oncotarget. 2015 Apr 10;6(10):7701-12.

3.

The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.

Canon J, Osgood T, Olson SH, Saiki AY, Robertson R, Yu D, Eksterowicz J, Ye Q, Jin L, Chen A, Zhou J, Cordover D, Kaufman S, Kendall R, Oliner JD, Coxon A, Radinsky R.

Mol Cancer Ther. 2015 Mar;14(3):649-58. doi: 10.1158/1535-7163.MCT-14-0710. Epub 2015 Jan 7.

4.

Discovery of AM-7209, a potent and selective 4-amidobenzoic acid inhibitor of the MDM2-p53 interaction.

Rew Y, Sun D, Yan X, Beck HP, Canon J, Chen A, Duquette J, Eksterowicz J, Fox BM, Fu J, Gonzalez AZ, Houze J, Huang X, Jiang M, Jin L, Li Y, Li Z, Ling Y, Lo MC, Long AM, McGee LR, McIntosh J, Oliner JD, Osgood T, Saiki AY, Shaffer P, Wang YC, Wortman S, Yakowec P, Ye Q, Yu D, Zhao X, Zhou J, Medina JC, Olson SH.

J Med Chem. 2014 Dec 26;57(24):10499-511. doi: 10.1021/jm501550p. Epub 2014 Dec 4.

PMID:
25384157
5.

Discovery of Potent and Simplified Piperidinone-Based Inhibitors of the MDM2-p53 Interaction.

Yu M, Wang Y, Zhu J, Bartberger MD, Canon J, Chen A, Chow D, Eksterowicz J, Fox B, Fu J, Gribble M, Huang X, Li Z, Liu JJ, Lo MC, McMinn D, Oliner JD, Osgood T, Rew Y, Saiki AY, Shaffer P, Yan X, Ye Q, Yu D, Zhao X, Zhou J, Olson SH, Medina JC, Sun D.

ACS Med Chem Lett. 2014 Jun 30;5(8):894-9. doi: 10.1021/ml500142b. eCollection 2014 Aug 14.

6.

Optimization beyond AMG 232: discovery and SAR of sulfonamides on a piperidinone scaffold as potent inhibitors of the MDM2-p53 protein-protein interaction.

Wang Y, Zhu J, Liu JJ, Chen X, Mihalic J, Deignan J, Yu M, Sun D, Kayser F, McGee LR, Lo MC, Chen A, Zhou J, Ye Q, Huang X, Long AM, Yakowec P, Oliner JD, Olson SH, Medina JC.

Bioorg Med Chem Lett. 2014 Aug 15;24(16):3782-5. doi: 10.1016/j.bmcl.2014.06.073. Epub 2014 Jul 1.

PMID:
25042256
7.

MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways.

Saiki AY, Caenepeel S, Yu D, Lofgren JA, Osgood T, Robertson R, Canon J, Su C, Jones A, Zhao X, Deshpande C, Payton M, Ledell J, Hughes PE, Oliner JD.

Oncotarget. 2014 Apr 30;5(8):2030-43.

8.

Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.

Gonzalez AZ, Li Z, Beck HP, Canon J, Chen A, Chow D, Duquette J, Eksterowicz J, Fox BM, Fu J, Huang X, Houze J, Jin L, Li Y, Ling Y, Lo MC, Long AM, McGee LR, McIntosh J, Oliner JD, Osgood T, Rew Y, Saiki AY, Shaffer P, Wortman S, Yakowec P, Yan X, Ye Q, Yu D, Zhao X, Zhou J, Olson SH, Sun D, Medina JC.

J Med Chem. 2014 Apr 10;57(7):2963-88. doi: 10.1021/jm401911v. Epub 2014 Mar 27.

PMID:
24601644
9.

Selective and potent morpholinone inhibitors of the MDM2-p53 protein-protein interaction.

Gonzalez AZ, Eksterowicz J, Bartberger MD, Beck HP, Canon J, Chen A, Chow D, Duquette J, Fox BM, Fu J, Huang X, Houze JB, Jin L, Li Y, Li Z, Ling Y, Lo MC, Long AM, McGee LR, McIntosh J, McMinn DL, Oliner JD, Osgood T, Rew Y, Saiki AY, Shaffer P, Wortman S, Yakowec P, Yan X, Ye Q, Yu D, Zhao X, Zhou J, Olson SH, Medina JC, Sun D.

J Med Chem. 2014 Mar 27;57(6):2472-88. doi: 10.1021/jm401767k. Epub 2014 Mar 4.

PMID:
24548297
10.

Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development.

Sun D, Li Z, Rew Y, Gribble M, Bartberger MD, Beck HP, Canon J, Chen A, Chen X, Chow D, Deignan J, Duquette J, Eksterowicz J, Fisher B, Fox BM, Fu J, Gonzalez AZ, Gonzalez-Lopez De Turiso F, Houze JB, Huang X, Jiang M, Jin L, Kayser F, Liu JJ, Lo MC, Long AM, Lucas B, McGee LR, McIntosh J, Mihalic J, Oliner JD, Osgood T, Peterson ML, Roveto P, Saiki AY, Shaffer P, Toteva M, Wang Y, Wang YC, Wortman S, Yakowec P, Yan X, Ye Q, Yu D, Yu M, Zhao X, Zhou J, Zhu J, Olson SH, Medina JC.

J Med Chem. 2014 Feb 27;57(4):1454-72. doi: 10.1021/jm401753e. Epub 2014 Feb 5.

PMID:
24456472
11.

Rational design and binding mode duality of MDM2-p53 inhibitors.

Gonzalez-Lopez de Turiso F, Sun D, Rew Y, Bartberger MD, Beck HP, Canon J, Chen A, Chow D, Correll TL, Huang X, Julian LD, Kayser F, Lo MC, Long AM, McMinn D, Oliner JD, Osgood T, Powers JP, Saiki AY, Schneider S, Shaffer P, Xiao SH, Yakowec P, Yan X, Ye Q, Yu D, Zhao X, Zhou J, Medina JC, Olson SH.

J Med Chem. 2013 May 23;56(10):4053-70. doi: 10.1021/jm400293z. Epub 2013 May 6.

PMID:
23597064
12.

Structure-based design of novel inhibitors of the MDM2-p53 interaction.

Rew Y, Sun D, Gonzalez-Lopez De Turiso F, Bartberger MD, Beck HP, Canon J, Chen A, Chow D, Deignan J, Fox BM, Gustin D, Huang X, Jiang M, Jiao X, Jin L, Kayser F, Kopecky DJ, Li Y, Lo MC, Long AM, Michelsen K, Oliner JD, Osgood T, Ragains M, Saiki AY, Schneider S, Toteva M, Yakowec P, Yan X, Ye Q, Yu D, Zhao X, Zhou J, Medina JC, Olson SH.

J Med Chem. 2012 Jun 14;55(11):4936-54. doi: 10.1021/jm300354j. Epub 2012 May 9.

PMID:
22524527
13.

AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, inhibits angiogenesis in models of ocular neovascular diseases.

Oliner JD, Bready J, Nguyen L, Estrada J, Hurh E, Ma H, Pretorius J, Fanslow W, Nork TM, Leedle RA, Kaufman S, Coxon A.

Invest Ophthalmol Vis Sci. 2012 Apr 24;53(4):2170-80. doi: 10.1167/iovs.11-7381.

PMID:
22410553
14.

Improvement of the synthesis and pharmacokinetic properties of chromenotriazolopyrimidine MDM2-p53 protein-protein inhibitors.

Beck HP, DeGraffenreid M, Fox B, Allen JG, Rew Y, Schneider S, Saiki AY, Yu D, Oliner JD, Salyers K, Ye Q, Olson S.

Bioorg Med Chem Lett. 2011 May 1;21(9):2752-5. doi: 10.1016/j.bmcl.2010.11.027. Epub 2010 Nov 10.

PMID:
21123063
15.

Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody.

Coxon A, Bready J, Min H, Kaufman S, Leal J, Yu D, Lee TA, Sun JR, Estrada J, Bolon B, McCabe J, Wang L, Rex K, Caenepeel S, Hughes P, Cordover D, Kim H, Han SJ, Michaels ML, Hsu E, Shimamoto G, Cattley R, Hurh E, Nguyen L, Wang SX, Ndifor A, Hayward IJ, Falcón BL, McDonald DM, Li L, Boone T, Kendall R, Radinsky R, Oliner JD.

Mol Cancer Ther. 2010 Oct;9(10):2641-51. doi: 10.1158/1535-7163.MCT-10-0213.

16.

Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth.

Hashizume H, Falcón BL, Kuroda T, Baluk P, Coxon A, Yu D, Bready JV, Oliner JD, McDonald DM.

Cancer Res. 2010 Mar 15;70(6):2213-23. doi: 10.1158/0008-5472.CAN-09-1977. Epub 2010 Mar 2.

17.

Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction.

Allen JG, Bourbeau MP, Wohlhieter GE, Bartberger MD, Michelsen K, Hungate R, Gadwood RC, Gaston RD, Evans B, Mann LW, Matison ME, Schneider S, Huang X, Yu D, Andrews PS, Reichelt A, Long AM, Yakowec P, Yang EY, Lee TA, Oliner JD.

J Med Chem. 2009 Nov 26;52(22):7044-53. doi: 10.1021/jm900681h.

PMID:
19856920
18.

Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels.

Falcón BL, Hashizume H, Koumoutsakos P, Chou J, Bready JV, Coxon A, Oliner JD, McDonald DM.

Am J Pathol. 2009 Nov;175(5):2159-70. doi: 10.2353/ajpath.2009.090391. Epub 2009 Oct 8.

19.

Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors.

Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, Rasmussen E, Sun YN, Zhong D, Hwang YC, Evelhoch JL, Oliner JD, Le N, Rosen LS.

J Clin Oncol. 2009 Jul 20;27(21):3557-65. doi: 10.1200/JCO.2008.19.6683. Epub 2009 Jun 22.

PMID:
19546406
20.

Induction of BAIAP3 by the EWS-WT1 chimeric fusion implicates regulated exocytosis in tumorigenesis.

Palmer RE, Lee SB, Wong JC, Reynolds PA, Zhang H, Truong V, Oliner JD, Gerald WL, Haber DA.

Cancer Cell. 2002 Dec;2(6):497-505.

21.

REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species.

Ellisen LW, Ramsayer KD, Johannessen CM, Yang A, Beppu H, Minda K, Oliner JD, McKeon F, Haber DA.

Mol Cell. 2002 Nov;10(5):995-1005.

22.

Induction of the interleukin-2/15 receptor beta-chain by the EWS-WT1 translocation product.

Wong JC, Lee SB, Bell MD, Reynolds PA, Fiore E, Stamenkovic I, Truong V, Oliner JD, Gerald WL, Haber DA.

Oncogene. 2002 Mar 27;21(13):2009-19.

23.

Cascades of transcriptional induction during human lymphocyte activation.

Ellisen LW, Palmer RE, Maki RG, Truong VB, Tamayo P, Oliner JD, Haber DA.

Eur J Cell Biol. 2001 May;80(5):321-8.

PMID:
11432721
24.

E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis.

Müller H, Bracken AP, Vernell R, Moroni MC, Christians F, Grassilli E, Prosperini E, Vigo E, Oliner JD, Helin K.

Genes Dev. 2001 Feb 1;15(3):267-85.

25.

The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin.

Lee SB, Huang K, Palmer R, Truong VB, Herzlinger D, Kolquist KA, Wong J, Paulding C, Yoon SK, Gerald W, Oliner JD, Haber DA.

Cell. 1999 Sep 3;98(5):663-73.

26.

Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1.

Harkin DP, Bean JM, Miklos D, Song YH, Truong VB, Englert C, Christians FC, Ellisen LW, Maheswaran S, Oliner JD, Haber DA.

Cell. 1999 May 28;97(5):575-86.

27.

Chromatin, TAFs, and a novel multiprotein coactivator are required for synergistic activation by Sp1 and SREBP-1a in vitro.

Näär AM, Beaurang PA, Robinson KM, Oliner JD, Avizonis D, Scheek S, Zwicker J, Kadonaga JT, Tjian R.

Genes Dev. 1998 Oct 1;12(19):3020-31.

28.

SREBP transcriptional activity is mediated through an interaction with the CREB-binding protein.

Oliner JD, Andresen JM, Hansen SK, Zhou S, Tjian R.

Genes Dev. 1996 Nov 15;10(22):2903-11.

29.

Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues.

el-Deiry WS, Tokino T, Waldman T, Oliner JD, Velculescu VE, Burrell M, Hill DE, Healy E, Rees JL, Hamilton SR, et al.

Cancer Res. 1995 Jul 1;55(13):2910-9.

30.

Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway.

Chen CY, Oliner JD, Zhan Q, Fornace AJ Jr, Vogelstein B, Kastan MB.

Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2684-8.

31.

The DCC gene: structural analysis and mutations in colorectal carcinomas.

Cho KR, Oliner JD, Simons JW, Hedrick L, Fearon ER, Preisinger AC, Hedge P, Silverman GA, Vogelstein B.

Genomics. 1994 Feb;19(3):525-31.

PMID:
8188295
32.

In vivo cloning of PCR products in E. coli.

Oliner JD, Kinzler KW, Vogelstein B.

Nucleic Acids Res. 1993 Nov 11;21(22):5192-7.

33.

Discerning the function of p53 by examining its molecular interactions.

Oliner JD.

Bioessays. 1993 Nov;15(11):703-7. Review.

PMID:
8292000
34.

p53 Mutation and MDM2 amplification in human soft tissue sarcomas.

Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, Vogelstein B.

Cancer Res. 1993 May 15;53(10 Suppl):2231-4.

35.

Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53.

Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B.

Nature. 1993 Apr 29;362(6423):857-60.

PMID:
8479525
36.

SAM 1.1 and JOSH 4.4: two RFLPs within the human DCC gene.

Simons JW, Oliner JD, Cho KR, Kinzler KW, Vogelstein B.

Hum Mol Genet. 1992 Aug;1(5):352. No abstract available.

PMID:
1363875
37.

Amplification of a gene encoding a p53-associated protein in human sarcomas.

Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B.

Nature. 1992 Jul 2;358(6381):80-3.

38.
39.

Scrambled exons.

Nigro JM, Cho KR, Fearon ER, Kern SE, Ruppert JM, Oliner JD, Kinzler KW, Vogelstein B.

Cell. 1991 Feb 8;64(3):607-13.

PMID:
1991322
40.

Assessment of regional myocardial blood flow with myocardial contrast two-dimensional echocardiography.

Kaul S, Kelly P, Oliner JD, Glasheen WP, Keller MW, Watson DD.

J Am Coll Cardiol. 1989 Feb;13(2):468-82.

41.

Relationship between left ventricular systolic function and plasma clearance of 169Yb-DTPA in normal and ischemic dogs.

Kaul S, Watson DD, Oliner JD, Okada RD, Weyman AE, Strauss HW.

Nephron. 1987;47(2):144-9.

PMID:
3696319
42.

New technique for myocardial contrast echocardiography in the experimental canine model using a special cannula for selective left main coronary artery cannulation.

Spotnitz WD, Oliner JD, Gascho JA, Nolan SP, Kaul S.

J Clin Ultrasound. 1986 Nov-Dec;14(9):742-5. No abstract available.

PMID:
3098800

Supplemental Content

Loading ...
Support Center